All Comparisons
Tirzepatide vs Mazdutide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Tirzepatide: AMazdutide: C
| Attribute | Tirzepatide | Mazdutide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / Dual GLP-1/Glucagon Agonist |
| Evidence Rating | A — FDA Approved | C — Phase I–II Clinical Trials |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Approved in China: June 2025 for chronic weight management, September 2025 for type 2 diabetes. Phase 2 trials running in the United States. Not approved outside China. |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety ... | Mazdutide is a fatty acid-acylated peptide that activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 receptor agonism provides glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite reduction — the same mechanisms as other GLP-1 agonists. Th... |
| Half-Life | ~5 days (116 hours) | Suitable for once-weekly dosing (exact value not fully published) |
| Bioavailability | ~80% SC | — |
| Molecular Weight | ~4813.5 g/mol | ~4233.7 g/mol |
| WADA Status | Not Prohibited | Not Listed |
| Research Half-Life | ~5 days (116 hours) | Suitable for once-weekly dosing (exact value not fully published) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved: Mounjaro (T2D, adults and children 10+) and Zepbound (obesity/overweight with comorbidities, severe OSA including new sleep apnea approval). Compounding fully prohibited for 503B facilities. Prescription only. | Not FDA-approved. Eli Lilly sponsored the first-in-human work as LY3305677 and US phase 2 trials are ongoing (NCT06124807, NCT06817356, NCT05623839). Innovent holds China rights and runs the IBI362 programme there. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Tirzepatide | Mazdutide |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2023788-19-2 | N/A |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | N/A |
| Available Formats | 10mg, 30mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.